Prestige Consumer Healthcare (NYSE:PBH) Shares Down 10% - Time to Sell?

Key Points

• Prestige Consumer Healthcare's share price plummeted 10% on Thursday, reaching a low of $66.74, significantly lower than the previous closing price of $75.16.
• Analysts have mixed views on the stock, with four giving it a buy rating and three a hold rating, resulting in an average target price of $93.33.
• The company's recent earnings report showed a revenue increase of 7.0% year-over-year, with an EPS of $1.32, exceeding analyst expectations.

Prestige Consumer Healthcare Inc. (NYSE:PBH - Get Free Report)'s share price fell 10% on Thursday . The stock traded as low as $66.74 and last traded at $67.67. 66,096 shares traded hands during trading, a decline of 82% from the average session volume of 365,909 shares. The stock had previously closed at $75.16.

Analysts Set New Price Targets

Several research firms have recently weighed in on PBH. Wall Street Zen raised shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Saturday, July 5th. Royal Bank Of Canada raised shares of Prestige Consumer Healthcare to a "hold" rating in a report on Thursday, May 8th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $93.33.

Prestige Consumer Healthcare Stock Performance

The firm's 50 day moving average price is $80.00 and its two-hundred day moving average price is $82.19. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.82 and a current ratio of 4.20. The firm has a market cap of $3.33 billion, a PE ratio of 15.66, a PEG ratio of 2.22 and a beta of 0.43.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.30 by $0.02. Prestige Consumer Healthcare had a net margin of 18.86% and a return on equity of 12.87%. The firm had revenue of $296.52 million for the quarter, compared to analyst estimates of $289.36 million. During the same period last year, the business earned $1.02 EPS. Prestige Consumer Healthcare's revenue for the quarter was up 7.0% compared to the same quarter last year. On average, research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Kayne Anderson Rudnick Investment Management LLC acquired a new stake in Prestige Consumer Healthcare in the fourth quarter valued at about $84,932,000. Raymond James Financial Inc. purchased a new position in shares of Prestige Consumer Healthcare during the fourth quarter valued at approximately $42,593,000. Bessemer Group Inc. lifted its stake in shares of Prestige Consumer Healthcare by 10,053.1% during the fourth quarter. Bessemer Group Inc. now owns 295,050 shares of the company's stock valued at $23,041,000 after buying an additional 292,144 shares during the period. Invesco Ltd. lifted its stake in shares of Prestige Consumer Healthcare by 24.7% during the first quarter. Invesco Ltd. now owns 1,321,800 shares of the company's stock valued at $113,635,000 after buying an additional 261,537 shares during the period. Finally, BNP Paribas Financial Markets increased its position in Prestige Consumer Healthcare by 1,073.3% during the fourth quarter. BNP Paribas Financial Markets now owns 203,903 shares of the company's stock worth $15,923,000 after purchasing an additional 186,524 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.